Pharma channel feed – Endpoints News

Pharma channel feed

Sanofi beefs up cancer drug pipeline, paying cash hungry ImmunoGen $30M for full rights to oncology portfolio

8 years ago

Bristol-Myers Squibb adds to its roster of checkpoint combo studies, partnering with Array and Advaxis

8 years ago

J&J buys into Protagonist’s next-gen peptide story with $50M upfront and $940M in milestones

8 years ago

Sunovion slammed by FDA rejection of nebulized LAMA for COPD as rival lines up a competing NDA

8 years ago

As FDA looks to speed reviews even more, 2 policy experts want to restrict the price of drugs that win an accelerated OK

8 years ago

Another player drops out of the biosimilars business as shakeout continues

8 years ago

FDA experts wave through Pfizer's copycat of an anemia med from Amgen, J&J, but a legal challenge still remains

8 years ago

Scott Gottlieb has some ideas about blocking any more would-be Martin Shkrelis from price gouging

8 years ago

Right on the heels of a PhIII failure, Merck neuroscience doubles down with a new drug targeting tau

8 years ago

Mystery biotech Emmaus grabs groundbreaking FDA panel backing for sickle cell drug — after quietly scrapping $225M deal

8 years ago

Puma wins a big round in fight for neratinib OK as experts offer a crucial thumbs up

8 years ago

Novartis swings the ax again, this time aiming at 250 job cuts in the US

8 years ago

The FDA refuses to lift a clinical hold on Cel-Sci’s PhIII drug

8 years ago

Pioneering Merck makes another breakthrough with PD-1 star Keytruda, grabbing first OK for a cancer biomarker

8 years ago

Pfizer grabs a solid endorsement from FDA insiders for their knockoff of Amgen’s flagship drug Epogen

8 years ago

Trump administration doubles down on slashing the budget at NIH, FDA — with a user fee hike for biopharma

8 years ago

Regeneron, Sanofi win a delayed OK for rheumatoid arthritis IL-6 heavyweight sarilumab

8 years ago

FDA review raises some serious questions for Puma, but shares rocket up on positive notes

8 years ago

Top analyst says the tempest over drug prices will likely just die out without any major changes

8 years ago

The EMA rejects XBiotech’s cancer drug after an embarrassing PhIII — but they’re not giving up

8 years ago

Merck’s checkpoint star Keytruda grabs another FDA OK, steering past wreckage of a Roche disaster

8 years ago

Novartis is sending 500 jobs to the scrap heap while adding 350 ‘high-tech’ positions for growth

8 years ago

GlycoMimetics stock rockets up on the latest ‘breakthrough’ title in cancer R&D

8 years ago

AbbVie loses a round in the heavyweight biosimilar fight over Humira patents

8 years ago

First page Previous page 322 323 324325326 327 328 Next page Last page